The doctors have said that the new
treatment can improve response rates (increase the rate of tumour
shrinkage) and delay cancer progression.
"Trebananib is a
first-in-class peptide-Fc fusion protein (or peptibody) that targets
angiogenesis (the growth of new blood vessels into cancerous tumours) by
inhibiting the binding of both angiopoietin 1 and 2 to the Tie2
receptor," researchers said.
This is very different mechanism of
action than other agents that also effect angiogenesis by inhibiting
vascular endothelial growth factor (VEGF) such as bevacizumab, they
said.
Researchers said trebananib does not increase the risks of
hypertension and bowel perforation like bevaciuzmab but still has a
similar impact on tumour shrinkage and delaying cancer progression.
A
randomized clinical trial added trebananib or placebo to standard
chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian
cancer patient from 179 sites in 32 countries.
The trial, dubbed
TRINOVA-1, was run by Professor Bradley J Monk who directs the Division
of Gynaecologic Oncology at the University of Arizona Cancer Centre at
St Joseph's in Phoenix.
"This is an exciting new targeted
medication in treating recurrent ovarian cancer. Recurrent ovarian
cancer is almost always fatal and new treatments are desperately
needed," said Monk.
Read more Latest News from Lifestyle News
No comments:
Post a Comment